Background: In a context of scarce health resources and varied medical practices, the aim of this study was to compare cost-effectiveness of different screening strategies for hepatitis C virus among blood recipients. Methods: A cost-effectiveness model was used to test nine screening strategies in three survival categories. Three Markov models were used for three methods of follow-up. The marginal cost-effectiveness ratio was estimated to compare the screening strategies. Results: Hepatitis C virus serology by enzyme-linked immunosorbent assay and confirmation by detection of the virus RNA was proved to be the dominant strategy. The marginal cost-effectiveness ratios were for subjects under 40 and low-volume transfusion patients, 776,474 and 2,636,500 French Francs-1996 (about USD 111,000 and 376,650) per life-year gained, respectively. Sensitivity analysis showed that the marginal cost-effectiveness ratio was influenced by the prevalence and the survival rates. The lower marginal cost-effectiveness ratio was estimated at 690,221 French Francs-1996 per life-year gained. Conclusion: This study showed high costs and few life-years gained for the dominant strategy even for the more favourable risk group. New studies may be carried out for new screening and therapeutic strategies.
1 1.2% of the general population in France has been infected by the hepatitis C virus (HCV). The policy of mass screening for hepatitis C has been reassessed for several reasons. On the one hand it has high morbidity after a long evolution with a high risk of chronicity, cirrhosis, and hepatocellular carcinoma • and on the other hand, it has low incidence in the general population and a low annual mortality of 0.6 to 1.8%o (as shown by Jougla 4 and Seeff 5 ). The long term sustained response to interferon therapy is not in favour of mass screening. The risk of hepatitis C due to transfusion has decreased significantly since implementation of systematic screening for HCV among blood donors. In France, improvement of the sensitivity of screening tests using enzyme immuno assays (EIA) as well as the establishment of the hemovigilance system had a real impact. In recent decades, several recommendations on pre-and post-transfusion screening of transfused patients were urged by the French Ministry of Health. 7 -9 For 1994 7 -9 For , 1995 7 -9 For and 1996 , Pillonel has estimated the incidence rate of hepatitis C in blood recipients at 2.69 per 100,000 persons per year. 10 Nevertheless, up to 100,000 patients were infected. Trepo and Bailly estimated the prevalence rate in transfused subjects before 1991 to be about 3%." Thus, screening strategies are needed to detect previously or newly infected hepatitis C cases. Medical practices regarding hepatitis C screening and management are not homogeneous as already demonstrated by Nalpas 12 and one of our previous studies. The French Government has recommended the use of alanine aminotransaminase and third generation enzyme immuno assay before transfusion and 3 months after in cases of occasional transfusion, and twice a year in cases of high-volume or frequent transfusion.'-' In France, a context of scarce health resources and about 3 million blood recipients per year made it necessary to assess the various screening strategies using a cost-effectiveness analysis. Our study aimed at comparing the eight most frequently prescribed screening strategies.
METHODS
Three groups of blood recipients, as defined by Vamvakas, 1^ were evaluated. Group 1 consisted of young adults less than 40 years old. Group 2 included blood recipients who had received one to ten units of red blood cells (low-volume transfusion) or were hospitalized in a surgery department (orthopaedic, cardiac, gastro-intestinal and obstetric surgery) or were aged between 40 and 65. Group 3 included blood recipients who received over ten units of red blood cells (high-volume transfusion).
Model structure or design
In order to compare the screening strategies, a decisionanalytical model was built (figure I). The model was divided into four successive trees: i) the screening strategies; ii) the confirmation test; lii) the treatment
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choice; and IV) the Markov model of the evolution of the disease: its natural history or evolution with treatment.
• The screening strategies These were selected from a qualitative study of the screening strategies currently used in France. They included the following biological tests: alanine aminotransferase (ALT), a third generation enzyme immuno assay (E1A3), detection of hepatitis C virus RNA (HCV RNA), alanine amino-transferase plus a third generation enzyme immuno assay. These tests were used in two groups: tests prescribed only before transfusion and tests prescribed before and after transfusion, leading thus to eight screening strategies. A ninth strategy was 'no testing and no medical therapy'.
• The confirmation test HCV RNA excluded subjects who tested positive for one of the seven remaining strategies were confirmed for hepatitis C by detecting the HCV RNA. The pretherapeutic test was ALT if this test was not prescribed at screening. A liver biopsy was performed in the case of elevated ALT and its result expressed in the Knodell's score.
• The treatment A Knodell's score under 5 led to surveillance with ALT. After three successive normal ALT, true positive cases followed a Markov model of the natural history of the disease and no treatment was indicated. Interferon was the main treatment. It was administered whenever Knodell's score was equal to or greater than 5 and lesions of chronic hepatitis C were found at the liver biopsy. A liver transplantation was considered in the case of cirrhosis.
• The Markov models We used Markov models because, at the onset of the infection, patients often experience severe events like chronicity or cirrhosis. Probabilities derived from analysis of the current literature were used to construct Markov models according to Sonnenberg and Beck 15 and corresponding to three specific situations (figure 2).
-First, the evolution of hepatitis C with interferon treatment was modelled with eight stages: recovery, acute hepatitis, chronic hepatitis, cirrhosis, hepatocellular carcinoma, transplantation for cirrhosis and hepatocellular carcinoma, and complicated cirrhosis. The entry points corresponded to acute hepatitis or chronic hepatitis which are common indications for interferon therapy. Chronic hepatitis C could lead to compensated or uncompensated cirrhosis, which could, in turn, lead to hepatocellular carcinoma. -Secondly, the evolution of the stages of hepatitis for which no interferon treatment was indicated. This comprised seven stages: recovery, chronic hepatitis, cirrhosis, hepatocellular carcinoma, transplantation for cirrhosis and hepatocellular carcinoma, and complicated cirrhosis. There were no spontaneous recoveries. -Third, a Markov model was built taking into account false negative cases of the screening strategies and the hepatitis C of the 'do nothing' strategy. Six stages were represented: recovery, acute hepatitis, chronic hepatitis, cirrhosis, hepatocellular carcinoma, and complicated cirrhosis. In these three specific Markov models, the absorbent stage was death.
• Model outputs The model outputs were expressed in life-year gained in detected hepatitis cases. The cost-effectiveness ratio was expressed in cost per life-year gained and over a period of 30 years. Analyses were carried out from a health insurance point of view. All analyses were performed using SMLTREE software, version 2.90.
• Assumptions of the model When Knodell's score was equal to or greater than 5, only subjects with chronic hepatitis were treated. Patients who had a relapse were not treated again and their prognosis was identical to that of patients with no response. A KnodelPs score lower than 5 led to surveillance with three ALT tests within a year. The stage of the disease remained identical for a year in the case of low-volume transfusion. The liver biopsy had a specificity of 1 and there were no false positive cases. No healthy patient was treated. Liver transplantation was indicated only for cirrhosis. In false negative cases in a given screening strategy, we considered having the same natural history of the disease as that of the infected subjects without screening strategy. All the subjects screened positive were monitored or treated. No subject was lost to follow-up and none refused biopsy or treatment.
Data sources of the model
• Likelihood of events Estimations of the figures used for the natural history of hepatitis C were extracted from previously published studies. Progression rates were calculated as annual constant probabilities and according to the references in table I. The annual rate of chronicity of hepatitis C was estimated at 70% according to Di Bisceglie, Kiyosawa and Degos. 18 Long-term success was estimated from the meta-analysis of Poynard. 19 Survival curves of risk groups were calculated using data from Vamvakas.
14 They were modelled with equation (1) after comparison with mortality for hepatitis stages given by Vamvakas. 14 The least favourable mortality equation was chosen for each combination of hepatitis stage and risk group. Parameters of mortality curves relative to risk groups and hepatitis C stages are shown in the appendix. A second equation was adapted for mortality from hepatocellular cancer. This mortality was always greater than for the risk groups.
• Diagnostic values of the biological tests The intrinsic values of the tests were obtained from a review of studies extracted from Medline, Excerpta Medica and, the Current Contents for the EIA3, and from Medline, Embase, Pascal and the Current Contents for HCV RNA. We used the criteria of McMaster University for the critical appraisal of published studies. Sensitivity and specificity were calculated with a 95% confidence interval using the exact method of Conover. These were 0.5 and 0.9 for ALT, 0.97 and 0.99 for EIA3, and 0.99 and 0.999 for HCV RNA, respectively.
• Costs The perspective of the analysis is the health care system because most transfusions are performed in hospitals which depend on the French Government for their financial resources. All costs estimates are shown in table 2. The costs of the biological tests (ALT, EIA3 and HCV RNA) and of interferon were those found in a previous study carried out in 12 French hospitals. The cost of interferon therapy was calculated for two occurrences of treatment: a long-term response with 13 months of treatment and injection of 3 MU, three times a week, and no response after 12 weeks of treatment with injection of 3 MU a week. Costs were also calculated for liver biopsy, follow-up of hepatitis stages and transplantation. Data were communicated by the hepato-gastroenterology department of our teaching hospital. All costs were estimated in French Francs and standardized FF 1 = USD 0.13 = Euro 0.15 for 1996.
Sensitivity analysis A one-way and a two-way sensitivity analysis were performed on the ten-year survival rate, on the prevalence rate of hepatitis C, on the recovery rate after interferon In high-volume transfusions, the E1A3 screening strategy prescribed before and after transfusion, and confirmed by HCV RNA detection had the lowest undiscounted cost: 
Sensitivity analysis (table 4)
A sensitivity analysis was performed for subjects under 40 and for low-volume transfusion recipients subjects. The The total number of life-years gained and the total costs of the strategy were estimated. The number of blood recipients was evaluated for each risk group. Two parameters were calculated: total cost of the strategy and total number of life-years gained. The most favourable situation for the subjects under 40 showed a gain of 1,106 life-years for a total cost of 859.3 FF million. For subjects undergoing surgery, 400 life-years were gained for a total cost of 713 million FF while 200 life-years were gained for a total cost of 500 million FF for subjects with low-volume transfusion. In the case of high-volume transfusion, the total number of life-years gained varied between 10 and 200 for a total cost of the strategy varying between 100 and 200 million FF. 29 In the latter study, the MCER takes into account assessment, investigation, and treatment of chronic hepatitis. Many models compare different interferon regimens, such as those of Ray 30 or Bennett. 3 ' Our model was different because it took into account not only treatment, but screening and confirmation strategies. The originality of our model is the survival at each hepatitis C stage which counterbalances the annual mortality of a given risk group of blood recipients. The annual probabilities of progression between hepatitis stages are those commonly found in the literature. The annual incidence rate of chronic hepatitis is commonly above 60%. The annual incidence rate of hepatocellular carcinoma following chronic hepatitis ranged from 1.4 to 7% according to Ikeda, 32 Fattovich 33 and Oka. 34 High costs with few life-years gained may be explained by short-survival groups despite the long life expectancy in chronic hepatitis C, by the costs of treatment, and by the long follow-ups for different stages.
DISCUSSION
The efficacy unit we used, life-years gained, was chosen by Bennett 28 and by the Canadian Office of Health Technology Assessment.
35 Indicators of quality of life could not be integrated into this study because the followup time was too long. A 30-year period was chosen for the analysis according to the interval found between blood transfusion and diagnosis of the last evolutive HCC stage.
36
To improve the accuracy of the estimations in future studies, the model should take into account early treatment of the disease and compensation of blood recipients, and introduce new stages of chronic hepatitis and cirrhosis with available data. Prospective studies similar to those performed for breast or colorectal cancer would be more convenient and accurate to estimate cost-effectiveness ratios of screening and management of hepatitis C. They should particularly focus on the natural history of hepatitis C, which is still inaccurately known. Studies of the natural history of hepatitis C, such as those of Seeff" could enable a better knowledge of this disease.
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In the two equations, t represents the time in years and varies between 0 and 30.
